Skip to content

Educational reference only. Not medical advice. Nothing on this site is for sale.

October 28, 2026CompoundingHHS lets 503A pharmacies compound six peptides under an interim enforcement discretion policyOctober 28, 2026Trial resultRetatrutide beats Ozempic on blood sugar and weight in head-to-head TRANSCEND-T2D-2 trialOctober 23, 2026FDA approvalFDA extends once-weekly insulin icodec (Awiqli) to children 10 and older with type 2 diabetesOctober 21, 2026CompoundingCitizen petition asks FDA not to allow compounding of seven peptides reviewed by its advisory committeeOctober 1, 2026Trial resultSurvodutide SYNCHRONIZE-2 phase 3 results in obesity with type 2 diabetes published in NEJMSeptember 30, 2026Trial resultEloraTZP (eloralintide plus tirzepatide) phase 2 results presented at EASD 2026September 30, 2026Trial resultOrforglipron ACHIEVE-4 cardiovascular safety trial published in The LancetSeptember 29, 2026Trial resultFull TRIUMPH-2 retatrutide results published in The LancetSeptember 24, 2026FDA approvalFDA approves insulin efsitora alfa (Onswik), a once-weekly basal insulin for type 2 diabetesSeptember 21, 2026WADAWADA publishes 2027 Prohibited List, naming peptides as examples of non-approved substances

October 28, 2026CompoundingHHS lets 503A pharmacies compound six peptides under an interim enforcement discretion policyOctober 28, 2026Trial resultRetatrutide beats Ozempic on blood sugar and weight in head-to-head TRANSCEND-T2D-2 trialOctober 23, 2026FDA approvalFDA extends once-weekly insulin icodec (Awiqli) to children 10 and older with type 2 diabetesOctober 21, 2026CompoundingCitizen petition asks FDA not to allow compounding of seven peptides reviewed by its advisory committeeOctober 1, 2026Trial resultSurvodutide SYNCHRONIZE-2 phase 3 results in obesity with type 2 diabetes published in NEJMSeptember 30, 2026Trial resultEloraTZP (eloralintide plus tirzepatide) phase 2 results presented at EASD 2026September 30, 2026Trial resultOrforglipron ACHIEVE-4 cardiovascular safety trial published in The LancetSeptember 29, 2026Trial resultFull TRIUMPH-2 retatrutide results published in The LancetSeptember 24, 2026FDA approvalFDA approves insulin efsitora alfa (Onswik), a once-weekly basal insulin for type 2 diabetesSeptember 21, 2026WADAWADA publishes 2027 Prohibited List, naming peptides as examples of non-approved substances

Peptide CompendiumLanguageSign in

Blend or stack

CJC-1295 + GHRP-2

Another GHRH-analog-plus-secretagogue pairing, based on the same reasoning as CJC-1295 + ipamorelin.

What is in it

Growth hormone axisEarly human dataFlashcard

CJC-1295

CJC-1295 with DAC · CJC-1295 without DAC

CJC-1295 is a lab-made, modified version of the active part of growth-hormone-releasing hormone.

Growth hormone axisEarly human dataFlashcard

GHRP-2

Pralmorelin · KP-102

GHRP-2 is a small synthetic peptide that strongly triggers growth hormone release by acting on the ghrelin receptor.

Is there evidence for the combination?

The GHRH-plus-GHRP synergy was shown in single-dose studies in healthy men ¹. We found no study of CJC-1295 combined with GHRP-2.

Each ingredient at a glance

Ingredient	Evidence	US FDA status	Sports (WADA)
CJC-1295	Early human data	Not FDA-approved; development discontinued	Prohibited at all times (S2.2.4 GHRH and analogues; CJC-1295 named)
GHRP-2	Early human data	Not FDA-approved in the US	Prohibited at all times (S2.2.4 GHRPs; GHRP-2/pralmorelin named)

Mixing adds unknowns. A blend carries the risks of every ingredient, and the interactions are untested. Vial contents and ratios are set by sellers and are not standardized. See each ingredient page for safety and legal details.

Sources

Bowers CY et al. J Clin Endocrinol Metab 1990;70(4):975